Background: Breast cancer is the leading female cancer worldwide and in Iraq .Some mutations, particularly in BRCA1, significantly increase the risk of the disease. Objectives: To demonstrate the frequency of BRCA1 in a group of high risk women with "positive family history'' of breast cancer; correlating the immune expression of BRCA1 with some parameters of known prognostic significance. 2015; Vol.57, No.3 Received: Feb, 2015 Accepted:June,2015 Introduction:
Introduction:
Breast cancer is the leading female cancer worldwide (1) , and in Iraq (2) . It has been recorded that in the UK and USA, approximately one in every ten women will contract the disease in their lifetime (3) . It is also amongst the leading cause of death in the female population in industrialized countries (1) . Prognosis and survival rates for breast cancer vary greatly depending on the cancer type, stage, treatment, and geographical location of the patient. Survival rates in the Western world are high (4) . It has been estimated that more than 8 out of 10 women (about 80%) in England diagnosed with breast cancer survive for at least 5 years (5). In developing countries, however, survival rates are much poorer (5) . Apart from positive familial history of breast cancer, the risk significantly increases in some mutations, particularly in BRCA1, BRCA2 and p53 genes expressions. In less than 5% of cases, genetics plays a more significant role by causing a hereditary breast-ovarian cancer syndrome (6) .This includes those who carry the BRCA1 and BRCA2 gene mutations (7) . These mutations account for up to 90% of the total genetic influence with a risk of breast cancer of 60-80% in those affected (8) .The BRCA1 gene and its protein products have recently been the subject of intensive investigation because of their proven role in hereditary human breast and ovarian cancers (8) .
Materials and Methods:
This cross-sectional designed (retrospective) study and recruited a total of 82 female patients diagnosed with breast cancer at the Main Referral Training Center for Early Detection of Breast Tumors (Oncology Teaching Hospital/ Medical City) and the Iraqi National Cancer Research Center (Baghdad University). The age of the patients in this study group ranged between 24 and 67 years. All patients were subjected to the Triple Assessment Technique (including Physical Breast Examination, Mammography and Fine Needle Aspiration Cytology FNA). Paraffin-embedded tissue blocks containing diagnostic histolological tissues of those patients were collected from February 2014. Nottingham modification of the Bloom-
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Richardson (9) was used in grading mammary carcinoma while staging was carried out according to the American Joint Committee on Cancer (AJCC)(10). Two histological types were identified: infiltrative ductal carcinoma) IDC73 -patients) and infiltrative lobular carcinoma (ILC -9 patients). Immunohistochemistry was performed utilizing four sections of 5 micron thickness, stained using Dako REAL™ EnVision™ Detection System, Peroxidase / DAB. One section for assessing the BRCA1 oncogne using Anti-BRCA1, GLK-2,a mouse monoclonal antibody. A case of infiltrative ductal carcinoma of breast was used as a positive control. Two sections were stained for (ER) and (PR), using mouse IgG1 antibody to Estrogen byDako and monoclonal mouse IgG1 antibody to progesterone by Dako). Normal breast cells in the sample were used as internal positive controls for both ER and PR. The criteria of positive reaction for ER, PR included the observation of dark brown intra-nuclear precipitate. The forth section was treated by Her2neu monoclonal antibody (rabbit anti-human Her-2 protein byDako). Positive control was prepared from positive tumor control sections which were processed with each set of staining for the HER-2 immunohistochemistry. The membrane staining intensity and pattern of HER-2 / neu expression were considered for scoring according to the breast cancer HER-2/ neu scoring system (11). In the current study, the positive BRCA1 reported only in the cytoplasm of tumor cells of breast cancer patients. The Anti-BRCA1, GLK-2, a mouse monoclonal antibody used in this study, was directed against the C-terminal region of BRCA1 and seemed to reveal only the cytoplasmic form of this protein (12) . Tumor cells were scored depending on the percentage of labeled malignant cells: (13) 1. Score 0 (-ve) for BRCA1 : Tumor cells staining less than 10% .
2. Score 1(+): Staining observed in 10% -40%. 3. Score 2 (++): Staining observed in 40%-70% 4. Score 3 (+++): Staining observed in greater than 70% . Staining was considered positive when greater than 10% of the tumor cells showed positive staining (13) . Statistical Analysis: Statistical analysis was used to compare the clinicopathological data pertaining to breast cancer patients with positive family history of the disease with immunohistochemical expressions of BRCA1, ER, PR and Her2 neu.SPSS V. 17(statistical package for social sciences) was utilized for data input and analysis (14) .
Results:
Eighty two female patients, who complained of breast lumps that were diagnosed as malignant, were enrolled in the study. Fifty of those patients had a positive family history (FH) of breast carcinoma (familial breast cancer) while 32 did not have any family history. The age range was (24-67 years) at the time of diagnosis with a mean of (48.07) and BMI of (30.38).
In those who had positive FH of breast cancer (n=50), 28 had an affected 1st degree relative while 22 had an affected 2nd degree relative. The patients were divided into two groups according to BRCA1 oncogene expression : Those with -ve BRCA1 (n=50) and those with +ve BRCA1 (n=32); the latter was further sub divided into score 1 (n=4), score 2 (n=13) and score 3 (n=15). In General, in our study all patients were divided to four main categories according to the FHx and BRCA1 immunohistochemistry results as shown in Figure ( There was significant relationship between BRCA1 expression in those with family history of breast cancer P-value 0.001 (p-value < 0.05) . The patients were divided into two age groups: first ( =< 45 year ) and second (> 45 year ) . The peak expression was seen in the first age group with BRCA +ve & FH+ve ( 54.3%). There was significant statistical difference in the expression within the different two age groups P-value 0.002 (< 0.05) . In study sample ER -ve expression was seen in (62.5%) of patients in group BRCA+ve & FH + . There was statistically significant association between the distribution of patients in the study group and the ER expression, P value 0.000. There was statistically significant association between the distribution of patients in the study group and the PR expression, P value < 0.009.
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The frequency of diagnosing Infiltrative Ductal Carcinoma (IDC) was 89% among total patients in the study sample, while 10.9% were diagnosed with Infiltrative Lobular Carcinoma (ILC). Among those patients showing BRCA +ve & FH +ve, IDC was seen in 81.4%, and ILC in 18.5%. There was no statistically significant association between the distribution of patients in the study group and the following parameters: number of parity, contraceptive pill consumption, age at Menarche, Body Mass Index, tumor pathological type, stage of the disease, tumor grade and the lymph node status.
Discussion:
In Iraq, breast cancer constitutes about one fourth of the registered cancer cases among the Iraqi population according to the latest Iraqi Cancer Registry(2). World Health Organization (WHO) displayed that the low survival rates in less developed countries, including Iraq, is mainly attributed to the lack of early detection programs coupled with inadequate diagnostic and treatment facilities (15, 16) .In the present series the average age of the patients at presentation was 48.07() years. Comparable findings were recorded in other Iraqi studies (2, 17 ) , which shows a trend for the disease to affect younger age groups. On the other hand, the peak age frequency of breast cancer in western countries is usually observed in the sixth decade and over (15, 16 ) . In present study 50 patients 60.9% out of the total cases documented family history of breast cancer. It has been demonstrated that out of those patients aged (< 45 years), 42.9% gave family history of breast cancer in their first degree relative and 25.7% had second degree relatives. A Comparable study from India revealed 20.7% of patients with breast cancer had positive family history of cancer (18) , while earlier studies on randomly selected breast cancer patients revealed that 14-16% had positive family history( 19 ) . The higher rate of positive family history in our study is obviously attributable to the selection criteria(age and family history of breast cancer) in which 50 out of 82 patients documented a positive family history of breast cancer either in first or second degree relatives. Relative indications for testing for a mutation in BRCA1 include a family history among first or second, degree relatives with any of the following conditions: breast cancer diagnosed at age 50 or younger, primary multiple breast cancers in the same or opposite breast in an individual, ovarian cancer, both ovarian and breast cancers, breast cancer in males (20) . Our aim was to target the cytoplasmic form of BRCA1 protein, considering that an abnormal location could be an indicator for BRCA1 mutation (at least in exon 11). Similar to other investigators, we attempted to chose a monoclonal antibody that has been shown to detect only the cytoplasmic form of BRCA1 protein (12) . In our study the BRCA1 expression was significantly correlated with family history where by 54% of patients with positive family history had positive expression of BRCA1. In particular, BRCA1 positive expression was significantly correlated with the two stratified age groups «equal or less than 45 years» and «above 45 years». It was confirmed that that BRCA1 expression was statistically higher in the younger age groups (less than 45 years). Rather close findings were reported in another study from Egypt (21). and comparable results were also reported by a study from Iraq(22), while slightly higher frequencies were observed by others ( 23) .Two studies from Kuwait (24) and Japan (25) , showed positive BRCA1 staining in 64.6% and 65.7% of breast cancer specimens respectively.In a report from Algeria (26) , it was observed that about 55 % of breast cancer cases were diagnosed in women younger than 50 years. It was reported that the lower age of onset of breast cancer in Algerian could suggest the involvement of genetic factors such as mutation of BRCA1. In China (27) , it was found that 71.42% of those with BRCA1 positive expression and positive family history belong to younger age groups. It has been proposed that these contradictory findings probably result from differences in the quality and specificity of the antibodies used, the different fixation methods utilized, quality of the archival paraffin embedded tissues which affect protein detection and the presence of splice variant isoforms of the BRCA1 protein in the tumors (28) . In the present study among patients with BRCA1 positive expression, 71.9 % revealed negative ER expression and 57.9% showed negative PR expression. It has been shown that most breast cancers in women with germ line BRCA1 mutations are estrogen receptor negative and typically lack expression of progesterone receptor (PR) and human epidermal growth factor receptor (HER)2 over expression (the so-called 'Triple-Negative' breast cancers) (29, 30) . It has been suggested that the association of ER negativity in breast cancer with BRCA1 mutation carrier status propose a tendency to regard all patients with ER positive tumors as non familial (31) .In China (27) , it was revealed that 85.7% of patients with positive BRCA1 expression and family history of breast cancer express negative ER receptor content, while in Australia (32), 58.1% of that group expressed negative ER receptor content. In USA(33), it was found that 77% of those with BRCA1 positive expression and positive family history had negative ER content and 86.7% showed negative PR. In the present study, there was no statistically significant correlation between BRCA1positive expression and Her2neu IHC expression. That might be attributable to the limited number of cases included and / or the quality of the utilized antibody survey.In this study, among patients with positive family history and BRCA1 positive expressions, 81.4% were diagnosed with IDC, while ILC was diagnosed in 18.5%. It has been reported in the literature that patients with (IDC) have a poor survival compared to other types (34 (35) . Other investigators demonstrated that most BRCA1-associated ER negative tumors are often high-grade IDC (36) . The present study found that 59.25% of breast carcinomas were graded as II while 40.7% were grade III . About 78% of cases with positive family history and BRCA1 positive expressions presented at the time of diagnosis with positive lymph node metastasis. Over 88 % of cases with positive family history and BRCA1 positive expressions were diagnosed in Stages II, III and IV. That fact attracts the attention to the probability of high prevalence of poorly differentiated breast carcinomas among Iraqi patients that was emphasized earlier by the reports of Al Alwan from Iraq (37, 38); where she documented that 81% of her studied cases exhibited aneuploid DNA patterns with aggressive behavior (39, 19) .
Conclusions:
BRCA1 expression had significant association with age, family history of the breast cancer and hormones (estrogen and progesterone) receptor contents. BRCA1 gene expression determination in patients with positive family history should be promoted and validated to serve as indicators for early diagnosis of the disease.
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